BioSpace News Archive

The financing supports the ongoing construction of SHINE’s medical isotope production facility and its commercialization of diagnostic and therapeutic isotopes, including molybdenum-99 (Mo-99) and lutetium-177

Addition of Elevate and Elevate Plus Bring Total GEHA FEHB Plan Offerings to Five

Dr. Amen will address how neuroscience is disrupting psychiatry and helping to prevent or reverse mental health issues

GRAIL, Inc. announced that Matthew P. Young has been appointed Chief Operating Officer and Chief Financial Officer effective October 28, 2019.

DURECT Corporation (Nasdaq: DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque psoriasis

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage company and leader in gene therapy using non-viral vector transfection delivery, wishes to draw attention to additional research in the field validating non-viral vector delivery as the next evolution in gene therapy.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal Investigator and Director of R&D, will serve as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the Company’s Vision Restoration Program at Neuroscience 2019,

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the issuance of patent, US 10,407,729, further expanding the company’s intellectual property and leadership position.

Citius Pharmaceuticals, Inc. (“Citius”) (“Company”) (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that the data cutoff for the most recent patient treated and completing 8 weeks of observation has been reached.

Panelists feature Valensa saw palmetto quality experts and USP’s Edward Wyszumiala, discussing value of USP verification